Abstract

Background Due to restorative concerns, bone regenerative therapies have garnered much attention in the field of human oral/maxillofacial surgery. Current treatments using autologous and allogenic bone grafts suffer from inherent challenges, hence the ideal bone replacement therapy is yet to be found. Establishing a model by which MSCs can be placed in a clinically acceptable bone defect to promote bone healing will prove valuable to oral/maxillofacial surgeons. Methods Human adipose tissue-derived MSCs were seeded onto Gelfoam® and their viability, proliferation, and osteogenic differentiation was evaluated in vitro. Subsequently, the construct was implanted in a rat maxillary alveolar bone defect to assess in vivo bone healing and regeneration. Results Human MSCs were adhered, proliferated, and uniformly distributed, and underwent osteogenic differentiation on Gelfoam®, comparable with the tissue culture surface. Data confirmed that Gelfoam® could be used as a scaffold for cell attachment and a delivery vehicle to implant MSCs in vivo. Histomorphometric analyses of bones harvested from rats treated with hMSCs showed statistically significant increase in collagen/early bone formation, with cells positive for osteogenic and angiogenic markers in the defect site. This pattern was visible as early as 4 weeks post treatment. Conclusions Xenogenically implanted human MSCs have the potential to heal an alveolar tooth defect in rats. Gelfoam®, a commonly used clinical biomaterial, can serve as a scaffold to deliver and maintain MSCs to the defect site. Translating this strategy to preclinical animal models provides hope for bone tissue engineering.

Highlights

  • Due to restorative concerns, bone regenerative therapies have garnered much attention in the field of human oral/maxillofacial surgery

  • Progenitor Cells Isolated from the Stromal Vascular Fraction Are mesenchymal stem cells (MSCs)

  • We evaluated the osteogenic differentiation potential of Human MSCs (hMSCs) by profiling the expression of genes strongly associated with osteogenesis

Read more

Summary

Introduction

Bone regenerative therapies have garnered much attention in the field of human oral/maxillofacial surgery. Histomorphometric analyses of bones harvested from rats treated with hMSCs showed statistically significant increase in collagen/early bone formation, with cells positive for osteogenic and angiogenic markers in the defect site. This pattern was visible as early as 4 weeks post treatment. Gelfoam®, a commonly used clinical biomaterial, can serve as a scaffold to deliver and maintain MSCs to the defect site Translating this strategy to preclinical animal models provides hope for bone tissue engineering. Cell-based therapies offer the potential to overcome these challenges, especially in dental and craniofacial healing [1, 2] This is a challenge in cases of larger defects or defects that are of complex anatomical shapes and sizes and require strong, mature bone regeneration for future implants. Tooth extraction procedures are considered to be a major risk

Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call